Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | OSBP | P22059 | 1/20 | 0.63 |
| ▸ | RORC | P51449 | 1/20 | 0.63 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.63 |
| ▸ | POLA1 | P09884 | 1/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.57 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318120 | 0.90 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2221515 | 0.90 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2637585 | 0.90 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27975861 | 0.89 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963054 | 0.89 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL6060845 | 0.89 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2638134 | 0.89 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963051 | 0.89 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL22194041 | 0.88 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL22194040 | 0.88 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114455-A1 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH | 2025-04-10 | — | — | US | disclosed |
| EP-4469057-A1 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | University of Georgia Research Foundation, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240350662-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | DNARx (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240277740-A1 | TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTION WITH LIPID AGENTS | VIRATIDES, LLC | 2024-08-22 | — | — | US | disclosed |
| US-20240156960-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | DNARx (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240033376-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | DNARx (US) | 2024-02-01 | — | — | US | disclosed |
| CN-116615233-A | Systems and methods for expressing biomolecules in a subject | DNARX公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023147552-A1 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4216935-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | Dnarx (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116392609-A | Systems and methods for in vivo nucleic acid expression | DNARX公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3349730-B1 | SYSTEMS FOR NUCLEIC ACID EXPRESSION IN VIVO | DNARx (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3600428-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | Dnarx (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190083653-A1 | Systems and Methods for Nucleic Acid Expression In Vivo | DNARx | 2019-03-21 | — | — | US | disclosed |
| US-20190046661-A1 | Systems and Methods for Nucleic Acid Expression In Vivo | DNARx | 2019-02-14 | — | — | US | disclosed |
| US-20180280539-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | DNARx | 2018-10-04 | — | — | US | disclosed |
| US-10086089-B2 | Systems and methods for nucleic acid expression in vivo | DNARx (US) | 2018-10-02 | — | — | US | disclosed |
| WO-2018175932-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | DNARx (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3349730-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | Dnarx (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20170080108-A1 | Systems and Methods for Nucleic Acid Expression In Vivo | DNARx | 2017-03-23 | — | — | US | disclosed |
| WO-2017049132-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | DNARx (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114455-A1 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | LIPA, DHCR7, LIPC | USP2 1422/4885CYP46A1 42/4885LMNA 101/4885 |
| US-20240156960-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | ACE2, ACE, IGF2BP2 | USP2 260/4885CYP46A1 3363/4885LMNA 2261/4885 |
| US-20240277740-A1 | TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTION WITH LIPID AGENTS | SPHK2, SGMS2, SPHK1 | USP2 1831/4885CYP46A1 1701/4885LMNA 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.